

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 15/12, 5/10, 1/21, C07K 14/71, 16/28, G01N 33/50, A61K 38/17		A1	(11) International Publication Number: WO 99/66038 (43) International Publication Date: 23 December 1999 (23.12.99)
(21) International Application Number: PCT/EP99/04109		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 11 June 1999 (11.06.99)			
(30) Priority Data: 9802130-6 15 June 1998 (15.06.98) SE 60/089,266 15 June 1998 (15.06.98) US 9804372-2 17 December 1998 (17.12.98) SE 60/114,386 29 December 1998 (29.12.98) US			
(71) Applicant (<i>for all designated States except US</i>): PHARMACIA & UPJOHN AB [SE/SE]; S-112 87 Stockholm (SE).		Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors; and			
(75) Inventors/Applicants (<i>for US only</i>): HOLMGREN, Lars [SE/SE]; Snackvagen 14, S-167 53 Bromma (SE). TROYANOVSKY, Boris [UA/SE]; Apartment 202, Rinkebysvangen 91 – Lagenhet 202, S-163 74 Spanga (SE).			
(74) Agent: MAZZINI, Giuseppe; Pharmacia & Upjohn S.p.A., Viale Pasteur, 10, I-20014 Nerviano (IT).			

(54) Title: ANGIOSTATIN-BINDING PROTEIN

EaHy926-vector

0h 1h 3h 6h

EaHy926-ABP1

0h 1h 3h 6h +Anglost.

p125 ►

(57) Abstract

The present invention provides the sequence of a protein capable of acting as an angiostatin receptor as well as the nucleic acid sequence thereof. The invention also relates to the use thereof in screening methods, wherein novel substances are created exhibiting the same advantageous anti-angiogenic properties as angiostatin.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Gulnea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ANGIOSTATIN-BINDING PROTEIN

Technical field

5 The present invention relates to the field of angiogenesis, and more specifically to novel molecules, such as proteins and peptides, whereby novel anti-angiogenic substances may be developed. The invention also relates to methods for developing such substances.

Background

10 Almost all of the tissue of a mammalian body comprises a fine mesh of very thin blood vessels, each of which is thinner than a human hair. Usually, neither the number nor the size of these vessels increase, since the division of the endothelial cells covering the vessels is slow, actually up to several years. The exceptions are for example during wound healing and menstruation, when the vessels grow rapidly. However, that is during a limited period of time and the cell division ceases thereafter.

15 The generation of new blood vessels from existing ones is called angiogenesis. Angiogenesis has been associated to cancer and the formation of tumors as well as to other conditions, such as diabetes retinopathy, rheumatoid arthritis and even some inflammatory conditions. Accordingly, a considerable research effort is made world-wide to find ways of preventing and inhibiting the angiogenic process. If this were possible, tumor growth could
20 be controlled and useful therapies could be developed regarding the above mentioned conditions.

There exists numerous pieces of evidence showing that tumors are depending on *de novo* formation of blood vessels for expansion beyond a mass of a few mm³. The angiogenesis is triggered by factors secreted by the tumor cells. It has recently been
25 discovered that tumors through unleashed proteolytic activity generates peptide fragments, which show anti-angiogenic activities. One example is the molecule angiostatin, which is a fragment of plasminogen.

Plasminogen is a substance in blood plasma which, when activated, forms plasmin or fibrinolysin, an enzyme involved in the coagulation of blood. Plasminogen itself lacks any
30 detectable anti-angiogenic activity. It has been found (Judah Folkman et al, Harvard Medical School, Boston) that a part of this endogenous protein, more specifically the first four kringle domains, is capable of preventing the endothelial cells from dividing. This part

of plasminogen has been denoted angiostatin, and a great deal of research within this field is centred around this molecule. The prior art has shows that angiostatin inhibits endothelial cells specifically *in vitro* and blocks angiogenesis *in vivo*. Systemic treatments with subcutaneous injections of angiostatin induces *in vivo* dormancy in a wide range of tumors
5 in SCID mice (O'Reilly et al., Nature Med., vol. 2, p. 689, 1996). No detectable toxicity has been detected in these animals even after months of treatment. Angiostatin shows two levels of specificity: it induces apoptosis specifically in endothelial cells *in vitro* (Claesson-Welsh et al., Proc. Natl. Acad. Sci., USA, vol. 95, p. 5579, 1998) and only affects endothelial cells active in angiogenesis *in vivo*. It has not shown to negatively affect cells in
10 established vessels.

Angiostatin does indeed exhibit some advantageous properties, *inter alia* as it is an endogenous substance. However, the disadvantages associated with its possible use for medical purposes cannot be neglected. One is that the half life thereof is very short, it may be counted in hours, thereby requiring a frequent administration thereof. This far, the
15 efficiency thereof has proven to be rather low, which fact necessitates the use of large doses thereof. These two disadvantages are in themselves strong motives for directing further research towards the finding of alternative, smaller and/or more efficient molecules to be used as medicaments.

20 Summary of the invention

The present invention solves the problems associated with angiostatin as defined above by providing a human protein, which has been named "ABP-1", defined by its ability to bind a fragment of plasminogen, preferably the first four Kringle domains (K1-K4) thereof, the said fragment being characterized by anti-angiogenic biological activity.
25 ABP-1 comprises an amino acid sequence substantially similar to that shown in SEQ ID NO. 2. Variants and fragments of ABP-1 are encompassed in the present invention.

Also encompassed in the present invention are the homologs of ABP-1 in other species, especially in other mammals.

In a further aspect, the invention provides isolated nucleic acid molecules comprising
30 a sequence that codes for ABP-1 or for a polypeptide substantially similar to ABP-1, including its variants, fragments and homologs.

It is another object of the present invention to provide nucleic acid probes whose sequence is derived from SEQ ID NO.1; these probes may be used as research tools as well as in diagnostic methods, for example to detect and measure ABP-1 biosynthesis in tissues and cells.

5 Accordingly, it is an object of the present invention to provide a diagnostic method for detecting the presence and the amount of ABP-1 or its variants and fragments in tissues and cells.

The present invention also includes screening methods for identifying a compound capable of interacting with ABP-1 or its variants and fragments. The screening method can
10 be in any configuration well known to those skilled in the art.

It is a further object of the present invention to provide compounds identified with the said screening method and capable of modulating the biological activity of ABP-1 or its variants and fragments.

15 It is a further object of the present invention to provide a pharmaceutical composition comprising as active ingredient the compound identified with the above screening method.

It is still a further object of the present invention to provide antibodies directed against epitopes present in ABP-1 or its variants and fragments as well as cell producing the antibody.

20 It is a further object of the present invention to provide a vector comprising the nucleotide sequence of ABP-1 or its variants and fragments.

It is a further object of the present invention to provide a cell containing the above vector.

Definitions

25 In the present application, the following terms are used in the meanings defined below.

As used herein, the term "angiogenesis" relates to the generation of new blood vessels into a tissue or organ. As mentioned above, under normal physiological conditions, humans and animals undergo angiogenesis only in very specific restricted situations. For example,
30 angiogenesis is normally observed in wound healing, fetal and embryonal development and formation of the corpus luteum and placenta.

The term "endothelium" relates to the thin layer of flat epithelial cells, that lines serous cavities, lymph vessels and blood vessels. The term "endothelial inhibiting activity" relates to the capability of inhibiting the growth of endothelial capillary endothelial cells.

5 The term "an angiogenesis associated protein" relates to a protein capable of interacting in the angiogenesis, such as a receptor binding an anti-angiogenic substance.

The term "substantially similar", when used in reference to the amino acid sequence of SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4, means an amino acid sequence having an high degree of sequence homology to SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. A high degree of homology means at least approximately 80% amino acid homology. 10 preferably at least approximately 90% amino acid homology, more preferably at least approximately 95% amino acid homology and most preferably at least approximately 98% amino acid homology.

The term "specifically hybridizing to" refers to the binding, duplexing or hybridizing of a molecule only to a particular nucleotide sequence under stringent conditions when the 15 sequence is present in a complex mixture (e.g. total cellular) of DNA or RNA. The term "stringent conditions" relates to conditions under which a probe will hybridize to its target subsequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. Generally, stringent conditions are selected to be about 5°C lower than 20 the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. (As the target sequences are generally present in excess, at Tm, 50% of the probes are occupied at equilibrium). Typically, stringent conditions will be 25 those in which the salt concentration is less than about 1.0 M Na ion, typically about 0.01 to 1.0 M Na ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g. 10 to 50 nucleotides) and at least about 60°C for longer probes. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.

Brief description of the drawings

Figure 1 shows the binding of ^{125}I -labelled angiostatin and plasminogen to bovine microcapillary endothelial cells *in vitro*. Units in abscissa represent the fold molar excess of cold angiostatin and plasminogen, respectively.

5 Figure 2 shows the strategy for isolating angiostatin binding proteins.

Figure 3 shows the growth of positive yeast clones under selective conditions.

Figure 4 compares the binding of recombinant "Big-3" to angiostatin and plasminogen, respectively.

Figure 5 is a map over "Big-3".

10 Figure 6 shows the open reading frame (Frame 2) of the gene encoding the angiostatin receptor according to the invention. The other possible frames do not produce any putative protein.

Figure 7 shows the expression patterns of fetal and adult mRNA as well as endothelial cells.

15 Figure 8 shows the relative quantitation of ABP-1 gene expression in different tissue. See experimental section for more details.

Figure 9 illustrates (A) the cellular localization of GFP-tagged ABP-1 receptor in transiently transfected HeLa cells and (B) the reorganization of GFP-labeled ABP-1 after incubation with angiostatin. Figure 9C shows the binding of angiostatin to ABP-1. See the 20 experimental section for more details. Figure 9D is an immunostaining of ABP-1 in Human umbilical cord endothelial (HUVE) cells together with staining against F-actin with rhodamin-labelled phalloidin. ABP-1 is localized in focal adhesions and membrane ruffles (arrows).

Figure 10 illustrates the down regulation of ABP-1 associated kinase activity after 25 addition of angiostatin.

Figure 11 is an autoradiography of an SDS-PAGE demonstrating that ABP-1 mediates angiostatin-induced focal adhesion kinase activity. See experimental section for more details.

30 Detailed description of the invention

The present invention relates to an isolated human angiogenesis-associated protein capable of binding a fragment of plasminogen, preferably an N-terminal fragment, such as

kringle domains 1 to 4 and/or kringle 5. Thus, the protein of the invention acts as a receptor of plasminogen fragments, in particular as a receptor of angiostatin and/or kringle 5 domain of plasminogen. The protein of the invention can be synthesized by biological or chemical methods (e.g. recombinant gene expression and peptide synthesis). Recombinant techniques 5 include gene cloning or amplification by *in vitro* methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS) or the self-sustained sequence replication system (SSR). A wide variety of cloning and *in vitro* amplification methodologies are well-known to those skilled in the art. Examples of these techniques are e.g. found in Berger and Kimmel, *Guide to Molecular* 10 *Cloning Techniques*, Methods in Enzymology 152 Academic Press, Inc., San Diego, CA (Berger). The present invention includes proteins which comprise amino acid sequences substantially similar to those shown in SEQ ID NO.2, SEQ ID NO.3 and SEQ ID NO.4. A comparison of the protein sequence of SEQ ID NO. 2 with the sequences present in all available data bases showed a homology of 23.7% with a hypothetical protein of 15 *Caenorhabditis elegans* encoded by a putative open reading frame located in the central cluster of chromosome III of this organism (described in R. Wilson et al., Nature, vol.368, 3 March 1994, p. 32-38). No function has been attributed to this hypothetical protein.

According to the definition given above, it is to be understood that all polypeptides capable of binding a fragment of plasminogen and having an amino acid sequence which 20 has at least approximately 80% sequence homology, preferably approximately 90% sequence homology, more preferably approximately 95% sequence homology and most preferably approximately 98% sequence homology to SEQ ID Nos.2, 3 or 4, are contemplated as being included in the present invention. These variant forms may result, e.g., from alternative splicing or differential expression in different tissue of the same 25 source organism. The variant forms may be characterized by, e.g., amino acid insertion, deletion or substitution. A preferred variant form of ABP-1 is illustrated in SEQ ID NO. 3 (see below).

A particularly preferred embodiment of the present invention is a fragment of ABP-1 named Big-3 which will be described in greater details below and which includes the 30 angiostatin-binding domain of ABP-1 (SEQ ID NO. 4).

In a further embodiment, the present invention provides peptides which comprises at least about 5, preferably at least about 10 contiguous amino acid residues of SEQ ID NO 2

or any variant or fragment thereof. However, the most advantageous size of the peptide will be depending on the intended future use thereof and the present invention is not limited to the above stated number of amino acids residues.

Also included in the present invention are homologs of ABP-1 and Big-3 in other species, in particular in other mammals. The term "homolog" refers to proteins exerting substantially the same biological function of the proteins of the invention, regardless of the homology existing between the corresponding amino acid sequences.

In another aspect, the present invention relates to isolated nucleic acid molecules comprising a sequence that codes for the proteins and peptides of the invention, including the variants, fragments and homologs as defined above. In a preferred embodiment, the nucleic acid molecule has the sequence of SEQ ID NO. 1. This sequence presents a 5' (from nucleotide 1 to nucleotide 796) and a 3' (from nucleotide 2825 to nucleotide 6463) untranslated regions. In another preferred embodiment the nucleic acid molecule has the sequence from nucleotide 797 to nucleotide 2824 of SEQ ID NO. 1. In another preferred embodiment the nucleic acid sequence encodes the ABP-1 fragment named Big-3 (illustrated in SEQ ID NO. 4) and it comprises the nucleotide sequence from position 2180 to position 2608 of SEQ ID NO. 1. All the nucleotide sequences encoding the polypeptides of the invention and differing from the nucleotide sequence of SEQ ID NO. 1 or fragment thereof by way of the degeneracy of the genetic code, are considered part of the invention. Sequencing analysis has revealed the presence of a possible polymorphism in the codon 1199-1201 of SEQ ID NO. 1, wherein a codon for Asn, Ser or Asp may be present; a further region corresponding to nucleotide positions 1238 to 1246 of SEQ ID NO. 1 has been found to code for the tripeptide Glu-Leu-Ala or for the tripeptide Thr-Trp-Pro. These variations in the amino acid sequence of ABP-1 are illustrated in SEQ ID NO. 3 which constitutes another preferred protein of the invention. Also included in the present invention are nucleotide molecules encoding a homolog of ABP-1 or fragment thereof.

The present invention further comprises a nucleic acid capable of specifically hybridizing, under stringent conditions, to any one of the nucleic acid molecules of the invention described above.

Where the nucleic acids according to the invention are to be used as probes, it is often desirable to label the sequences with detectable markers. Such markers may include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical,

electrical, optical or chemical means. The markers may be incorporated by any of a number of means well known to those of skill in the art. Methods for detecting such markers are also well known in the art and disclosed in the literature. The probes find a useful application in diagnostic application, for example to detect and measure ABP-1 biosynthesis in tissues and cells.

In another aspect, the present invention provide screening methods or assays, wherein molecules that exhibit the same properties as angiostatin and/or kringle 5 are screened for. In a typical screening method a compound capable of activating the angiostatin signal transduction pathway is identified through a high throughput cell-based screen. Such screen rely on a reporter gene driven by an angiostatin responsive element that is stably transfected into an angiostatin-responsive cell line. The responsive element is linked to a reporter gene, e.g. the gene for luciferase; upon binding of the compound to the protein of the invention, the intracellular pathway is activated thus causing an increase in the reporter gene activity that can be detected.

The compounds identified through the screening method hereby described are within the scope of the present invention. Such compounds are preferably low molecular weight molecules of peptidic or non-peptidic nature. Thanks to their small size they are more practical for use for medicinal purposes, compared to angiostatin. These molecules and the uses thereof are described in more detail below.

The proteins and peptides according to the invention may be synthesized using standard chemical peptide synthesis techniques. For solid phase synthesis, see e.g. Barany and Merrifield, *Solid-Phase Peptide Synthesis*, pp 3-284 in *The Peptides: Analysis, Synthesis Biology, Vol. 2: Special Methods in Peptide Synthesis*, Part A.

Preferably, the proteins, peptides and polypeptides according to the invention are synthesized using recombinant DNA methodology, which generally involves creating a DNA sequence that encodes the protein or peptide, placing the DNA in an expression cassette under the control of a particular promoter, expressing the protein or peptide in a host, isolating the expressed protein or peptide and, if required, renaturing the product. Once expressed, the recombinant peptides or proteins can be purified according to standard procedures in the art. Thus, another aspect of the present invention is a vector, such as a virus or a plasmid, comprising a nucleic acid according to the invention. Further, the invention also encompasses a recombinant cell transformed or transfected with the said

vector expressing the present protein or peptide as well as a recombinant cell expressing the present antibody, which will be defined in more detail below. Vectors encoding the peptides and proteins according to the invention are useful in expressing those molecules to provide immunogens for antibody production. The vectors according to the invention are also useful 5 for transforming cells *in vitro* or *in vivo* to express the present peptides and proteins. Cells expressing any one of the present nucleic acids, such as the gene defined by SEQ ID NO 1, may be used in a wide variety of contexts and are also within the scope of the present invention. Such cells may be eucaryotic or procaryotic.

The proteins and peptides according to the invention can be used as antigens for 10 raising antibodies against the same. Consequently, the invention also encompasses an antibody which specifically binds a peptide according to the invention. Such antibodies are useful for immunoassays, e.g. for the isolation of peptides or polypeptides. The peptides according to the invention may also be used in assays, such as amplification specific assays, immunological assays *etc.*

15 The antibodies according to the invention may be monoclonal or polyclonal and include individual, allelic, strain or species variants, or fragments thereof, both in their naturally occurring (full-length) forms and recombinant forms. Additionally, the antibodies are raised to the present peptides or polypeptides in either their native configuration or in non-native configurations. Anti-idiotypic antibodies can also be generated. Many methods 20 of making antibodies are known to persons skilled in the art. For techniques for preparing monoclonal antibodies, see e.g. Stites et al (eds.), *Basic and Clinical Immunology* (4th ed), Lange Medical Publications, Los Altos, CA, and references cited therein. For techniques that involve selection of libraries of recombinant antibodies in phage or similar vectors, see e.g. Huse *et al.* (1989) *Science* 246:1275-1281.

25 The molecules according to the invention may be used in pharmaceutical preparations, especially for the treatment and/or prevention of angiogenesis related disorders. Accordingly, the invention relates to a peptide, polypeptide, protein or antibody according to the invention for use as a medicament as well as to the use of said molecules in the manufacture of a medicament directed towards an angiogenesis related disease or disorder. 30 The invention also relates to a pharmacological preparation comprising a molecule according to the invention together with a pharmaceutically acceptable carrier. The molecules used as medicaments according to the invention may be anyone of the above

described peptides, polypeptides, proteins or antibodies as well as any novel substance identified in a screening method using the same and described above.

Accordingly, the most preferred use of the present molecules is in assays, wherein novel substances are screened for. Compounds may be identified which exhibit similar anti-angiogenic effects as angiostatin and/or kringle 5, but which are smaller, more efficient and preferably exhibits a longer half time in a human or animal body than angiostatin. The shorter half time may be due to a lower tendency to be degraded by proteases. When an organic compound is designed, a molecule according to the invention is used as a "lead" compound. The design of mimetics to known pharmaceutically active compounds is a well known approach in the development of pharmaceuticals based on such "lead" compounds. Mimetic design, synthesis and testing are generally used to avoid randomly screening a large number of molecules for a target property.

Thus, such novel molecules are preferably used as medicaments that may be administered in much lower doses than angiostatin, and which may be administered less frequently, such as e.g. once every fourteen days, which is to be compared to the half time of angiostatin which is about ten times shorter. In a particular embodiment, the novel molecules identified by the screening methods according to the invention are low molecular weight organic molecules, in which case a pharmaceutical preparation may be prepared thereof for oral intake, such as in tablets.

The pharmaceutical preparations according to the invention may however be prepared for any route of administration, e.g oral, intravenous, cutaneous or subcutaneous, nasal, intramuscular or intraperitoneal. The nature of the carrier or other ingredients will depend on the specific route of administration. (Examples of techniques and protocols that are useful in this context are *inter alia* found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A (ed.), 1980.)

The dosage of these low molecular weight compounds will depend on the disease state or condition to be treated and other clinical factors such as weight and condition of the human or animal and the route of administration of the compound. For treating human or animals, between approximately 0.5 mg/Kg of body weight to 500 mg/Kg of body weight of the compound can be administered.

The present compounds and methods are advantageously used in relation to all kind of angiogenesis related disorders and/or diseases, such as tumor conditions, diabetes,

rheumatoid arthritis and even some inflammatory diseases, such as psoriasis, chronic inflammations of the intestines, asthma etc. It is also suggested that they may be used in order to treat and cure, or prevent, obesity.

In a particular embodiment, the present molecules are used in gene therapy. For a 5 review of gene therapy procedures, see e.g. Anderson. *Science* (1992) 256:808-813.

A further advantageous use of the present invention is to develop methods of regulating the signalling of the present angiostatin and/or kringle 5 receptor in the body and therefore, the invention also relates to methods of treating a human or animal patient suffering from an angiogenesis related disease or disorder as well as to methods preventing 10 such conditions.

EXPERIMENTAL

Below, the invention will be disclosed in more detail with reference to the drawings.

All references in the present disclosure and above are hereby incorporated in the 15 present application.

Evidence that angiostatin binds to endothelial cells

By competitive binding assays between angiostatin and the angiogenic factors, VEGF and bFGF, the present inventors have shown that angiostatin does not affect the ligand- 20 receptor interaction of these molecules. The same level of binding could be detected in the presence or absence of unlabeled angiostatin. Thus, it can be ruled out that angiostatin acts by blocking angiogenic factors interaction with endothelial cells.

The direct binding of angiostatin and its precursor plasminogen has been studied by binding assays using iodinated proteins and analyzing their interaction with bovine 25 microcapillary endothelial cells, see Figure 1.

In particular, human angiostatin (kringle domains 1-4) or plasminogen was labeled with iodine 125 by the Iodogen method according to the protocol of the manufacturer (Pierce Inc.). The labelled protein was then purified on a G50 sepharose column (Pharmacia 30 Inc.) The specific activity was estimated at 90 000 cpm/ng protein. For binding assays, bovine capillary endothelial cells were grown to confluence in 12 well plates. The cells were washed with PBS containing 1mg/ml bovine serum albumine (BSA). The cells were then incubated with 10ng/ml radio-labeled angiostatin or plasminogen. The binding was

competed with increasing concentrations of unlabeled ligand. Cells were incubated on ice for 2 hours. Cells were then washed five times with PBS+1mg/ml BSA. The cells were lysed with 1% Triton X100 in PBS and radioactivity was measured in a gamma counter. Dissociation constant and receptor numbers were estimated using the RBINDING program
 5 (van Zoelen EJ. Anal. Biochem. 1992 Feb 1;200 (2):393-9).

Identification of angiostatin binding molecules using the yeast two hybrid system

Angiostatin retains activity even after reduction, suggesting that three dimensional folding is not vital for binding and activity. This favours screening procedures wherein a
 10 large number of clones may be screened although protein refolding may be less accurate.

The yeast two hybrid system was employed to screen for molecules that bind kringle domains 1-4 of plasminogen. This is further disclosed below with reference to figure 2. Approximately 2×10^6 clones from a two hybrid cDNA library from human term placenta (Stratagene) were screened. Positives clones were identified in the following way:

15 (1) Screening under selective conditions (His-, Leu- and Trp-) generated 37 positive clones in yeast strain CG1945.

(2) Seven out of 37 clones displayed high β -galactosidase activity after incubation with ONPG (SIGMA) at 30^0C for 2h.

20 (3) The DNA from the seven colonies that contained high β -gal activity was purified and retransfected into yeast strain Y190. Three out of the seven colonies retained activity in the new yeast strain. Sequencing analysis of these clones revealed that they were derived from the same gene.

25 (4) Growth in the presence of 50mM 3-aminotriazol (Fig. 3) as well as β -gal activity (see table below) was assessed in Big 3 clones and compared to positive and negative controls.

Binding Domain	Activation Domain	β -Gal Activity
Angiostatin + Binding Domain	Big3 - Activation Domain	15 u
Angiostatin + Binding Domain	Activation Domain alone	<0.04 u
Binding Domain alone	Big3 - Activation Domain	0.07 u
p53 + Binding Domain	Big3 - Activation Domain	0.05 u
p53 + Binding Domain	SV40LT - Activation Domain	90 u

Sequence of Big 3 (angiotatin-binding domain)

After isolation of the big 3 clone from a placenta yeast two-hybrid library (Stratagene, Inc.), we directly sequenced the cDNA insert from the pGAD activation domain vector with GAL4 AD sequencing primers. The cDNA insert was recloned into pUC18 vector using 5 EcoR1 sites from adaptors and sequencing was repeated using universal and reverse primers. Sequences were analyzed in an ALF automated sequencer (Pharmacia). The sequence of Big 3 is shown in SEQ ID NO. 4.

Expression and purification of Big3 and Big3-GST fusion protein

10 Big3 sequence has been expressed in *E.coli* as fusion protein with the glutathione S - transferase (GST) domain from *Schistosoma japonicum*.

•*Vector construction:*

Big3 fragment (429 bp) was obtained by PCR amplification using pUC18-Big3 plasmid as template. Primer sequences were:

15 BamHI-NH₂ 5' TAC GGA TCC GAA TCG AAC AAA ACT GCA GCT G 3' (SEQ ID NO. 5)

XhoI- COOH 5' ATA CTC GAG TCA TGG AGC TGG AGT TGG AGC CA 3' (SEQ ID NO. 6)

The cycling protocol used was:

20 94°C 3', 60°C 1', 72°C 1' 1cycle

94°C 30'', 60°C 1', 72°C 2' 30 cycles

94°C 30'', 60°C 1', 72°C 5' 1cycle

Taq polymerase: native Pfu DNA polymerase (Stratagene)

PCR fragment was digested with BamHI and XhoI, purified and ligated to PGEX-6P-25 2 plasmid (Pharmacia Biotech) digested with the same restriction enzymes. Ligation mixture was used to transform XL1-Blue cells (Stratagene). Recombinant plasmids were verified by restriction analysis and automated sequencing.

•*Expression and purification:*

DH5α cells (Clontech) were transformed with one verified clone, named pGEX-Big3, and 30 induced for 6 hours, room temperature with 0.1 mM IPTG.

The fermentation broth was centrifuged at 4000xrpm 15 min and the cell pellet was resuspended in 10% w/v of lysis buffer (50 mM TRIS.HCl pH 8.0, 100 mM NaCl, 20 mM

DTT , 1 mM EDTA, protease inhibitor mix), and lysed by sonication. The total lysate was centrifuged at 15000 xg for 20 min at 4°C. The clarified supernatant was applied to a Glutathione-Sepharose column (1ml for 20 ml of lysate) preequilibrated with lysis buffer. The resin was washed with 10 column volumes (CV) of lysis buffer and the fusion protein 5 was eluted with 3 CV of elution buffer (100 mM TRIS.HCl pH 8.0 20 mM reduced glutathione).

GST-Big3 protein can be cleaved by incubation of the glutathione-Sepharose bound fusion protein with 20 μ l/ml resin of PreScission protease in PS buffer containing 50 mM TRIS.HCl pH 7.0, 100 mM NaCl, 1 mM EDTA, 1 mM DTT, 1 mM PMSF.

10 The eluted proteins behave like a single peak in rp-HPLC (10-90% gradient of acetonitrile in water plus 0,1% TFA), show the expected molecular size by mass analysis (electrospray) and the correct NH₂ sequence. In SDS-PAGE a contaminant appears at the apparent MW of 80 kD; it was demonstrated to be DnaK, a bacterial chaperone, which can be eliminated running an ion exchange chromatography on a HiTrapQ column.

15 The yields obtained from 1 litre of fermentation are about 10 mg of GST-Big3 fusion protein and about 3 mg of the cleaved Big3.

In vitro binding of recombinant GST-tagged Big 3 to angiostatin

The protocol used for binding is described here below.

20 One colony of pGEX-Big3 transformant was inoculated into 10 ml LB medium plus ampicillin and grown overnight at 37°C.

The overnight culture was diluted 1:10 into 100 ml fresh medium and after 1 hour of incubation at 37°C, IPTG was added to a final concentration of 0.5mM and incubation continued for 3 to 7 hours.

25 The culture was then centrifuged at 5000g for 10 minutes, the pellet was resuspended in 3-5 ml of ice-cold PBS and cells were lysed by sonication. Triton X100 was added to a final concentration of 0.5 - 1 % and 1.5 ml aliquots of the suspension were centrifuged at 14000 rpm for 10 minutes.

30 0.1-0.3ml of 50% slurry of glutathione-agarose.beads were added to the supernatant and mixed for 3-5 hour at 4°C. The beads were then collected by centrifugation and washed 5 times with ice-cold PBS and 2 times with binding solution (B.S.) consisting of: 50mM Tris pH7.5, 150mM NaCl, 0.5mM EDTA, 1mM DTT,1mM PMSF).

Binding assay: 0.7ml B.S., 0.1% calf serum, 500ng angiostatin were mixed with 30-50μl 50% slurry of Big3-immobilized glutathione-agarose beads for 1 - 3 hour at 4°C.

The resin was washed 5-7 times with ice cold B.S., then used for Western blot analysis using anti-human plasminogen antibodies (Dako Inc.).

5 Figure 4 shows how purified recombinant Big 3 binds angiostatin in vitro. Interestingly, binding of plasminogen could also be detected, but only after reduction of disulphide bonds by treating it with DTT.

10 Cloning of full-length sequence

Figure 5 illustrates the scheme for cloning the full-length sequence of ABP-1. The whole gene was cloned by screening a placenta cDNA phage library with a Big3 probe (with repetitive sequences removed) together with 5' RACE PCR (Gibco) using mRNA from human umbilical cord endothelial cells. The full sequence of the cDNA clone is disclosed in SEQ ID NO. 1, whereas the encoded protein is shown in SEQ ID NO. 2. Details of the experimental protocol are as follows.

10 million clones of a placenta lambda phage library (Stratagene, Inc.) were screened using a *HinfI* fragment of Big 3 as probe. DNA isolation and Southern blot procedures were performed according to established protocols (Sambrook et al 1989). We isolated 5 clones
15 (7-1, 7-2, 8-2, 9-3, 9-5) with sequences that overlap with Big3. The 5'-sequence of the 7-2 clone was used for designing Gene-Specific Primers (GSP) for 5'RACE PCR (Gibco Life technologies, Inc.). mRNA isolated from Human umbilical cord endothelial cells was used to identify 5' sequences.

Primers used for the first RACE PCR:

20 Primers: GSP1- (5' to 3') GCTGACAGTTGCCCTGACGCTGCT (SEQ ID NO. 10)
 GSP2- (5' to 3') CGGAGACGGTGCTTAGCTGCTCA (SEQ ID NO. 11)
 GSP3- (5' to 3') TCCTTCCAACTCTGCCTCAAGTTCCG (SEQ ID NO. 12)

30 RACE procedures have been used for amplification and cloning unknown sequences between the GSP2 and GSP3 and the 5'-end of the mRNA ABP-1. This sequence was then used to design new primers for the next set of RACE RCR:

Primers: GSP1-(5' to 3') GGTGGCAGCGGACAGGCAGGATAC (SEQ ID NO. 13)

GSP2 GAGGCGGAGAGAACTAAGAGAAGA (SEQ ID NO. 14)

GSP3 GAGCGGAGATGGAGGAGTAATTCA (SEQ ID NO. 15)

5 Clones A2-2, A2-1 and A1-C with overlapping sequences were isolated. The A2-1 sequence was used as probe for the second screening of the placenta phage library . From this screening we isolated another 2 clones (7-10 and 6-5). As shown in Figure 6, of the six possible frame the only one producing a complete open reading frame is frame 2, yielding a putative protein of 675 amino acid residues.

10

mRNA Expression pattern

A commercially (Clontech, Inc.) obtained multiple human adult and fetal tissue (#7760-1 and #7756-1) mRNA blots (2mg mRNA/well) was probed for ABP-1. The blots were hybridized with the ExpressHyb hybridization solution (Clontech, Inc.) according to the 15 protocol of the manufacturer. The blots were probed with the 7-2 5'PstI fragment. Figure 7 shows the results of the experiment; sizes are 9.5 and 7.5 kb.

ABP-1 was also detected in human umbilical cord, bovine aortic and bovine microcapillary endothelial cells. Little or no expression was detected in the immortalized endothelial cell-line EaHy926 and in human fetal fibroblasts. Neither of the cell lines 20 respond to angiostatin or exhibit any binding of FITC-labeled angiostatin.

Real time RT-PCR

The 5' nuclease assay (TaqMan assay) uses a nonextendable oligonucleotide hybridization probe (TaqMan Probe). The TaqMan probe consists of an oligonucleotide 25 with a 5'-reporter dye and a 3'-quencher dye. When the probe is intact, the proximity of the reporter dye to the quencher dye results in suppression of the reporter fluorescence, primarily by a Foster-type energy transfer. During PCR, forward and reverse primers hybridize to a specific sequence of the target DNA. The TaqMan probe hybridizes to a target sequence within the PCR product. The Taq Polymerase cleaves the TaqMan probe 30 with its 5'-3' nuclease activity. The reporter dye and quencher dye are separated upon cleavage, resulting in increased fluorescence of the reporter.

Real time RT-PCR analysisRNA Preparation

5 Isolation and purification of total RNA from tissues and cells listed below was performed using the Ultraspec RNA isolation system (Biotex).

HDMEC/2	h.dermal microvascular EC	poly A+
A2780	h.ovarian carcinoma	TOTAL
A375	h. melanoma	TOTAL
HDF	H.dermal fibroblasts	TOTAL
HELA	h.cervix carcinoma	TOTAL
DU145	h.prostate carcinoma	TOTAL
HUVEC	h.umbelical vein EC	TOTAL
ECV304	immortalized EC	TOTAL
CEM	h.acutelymphobl.leuk.	TOTAL
K562	h.erythroleukemia	TOTAL
JURKAT	h.acuteT-cellleukemia	TOTAL
THP-1	h.monocyte(acute leu)	TOTAL
EaHy926	h.dermal cells	TOTAL
S35/K9	human colon cancer	TOTAL
Brain	human normal tissue	TOTAL
Colon	human normal tissue	TOTAL
Prostate	human normal tissue	TOTAL
Skel.Muscle	human normal tissue	TOTAL
Uterus	human normal tissue	TOTAL
Placenta	human normal tissue	TOTAL

The RT reaction was performed using TaqMan Reverse Transcription Reagent (PE Applied Biosystems) with Random hexamers, as RT primers. The reaction volume for Reverse Transcription step was 100 µl and the total RNA amount was 1 µg for sample.

The RT was performed using the following cycling parameter:

5

10' at 25°C

45' at 48°C

5' at 95°C

10

PCR reaction

After a primer concentration optimization, the PCR reaction on 10 ng of the cDNA was performed using TaqMan Universal PCR Master Mix (PE Applied Biosystems) and the following oligonucleotides

- ABP-1 Forward Primer: 5' GTTGACCTGCAATCCAGACAA 3' (SEQ ID NO. 7) Final concentration 300nM
- ABP-1 Reverse Primer: 5' CCCAGGATCTGAATGGGAGTT 3' (SEQ ID NO. 8) Final concentration 900nm
- ABP-1 TaqMan Probe:
5' (FAM dye)-CAGATGGGCCTGTGTTCCACTCCAA-(TAMRA dye) 3' (SEQ ID NO. 9) Final probe concentration 200nM

The cycling protocols was:

2' at 50°C; 10' at 95°C 1 cycle

15'' at 95°C; 1' at 60°C 40 cycles

25

Relative Quantitation of gene expression

The Comparative method use an arithmetic formula to achieve the result for relative quantitation without need for Standard curve.

The result , depicted in Figure 8, indicate how many fold the sample X expresses the target relative to the Calibrator which is the sample that shows the lowest level of expression of the target. In this experiment EaHY926 sample was chosen as calibrator.

Antibodies against Big-3

For immunisation of New Zealand White rabbits, 100 micrograms of Big3-GST fusion protein were dissolved in 1 ml phosphate buffered saline (PBS) homogenised with 1 ml of Freund's Complete Adjuvant (Gibco). The resulting emulsion was injected 5 subcutaneously on day 0 and this treatment was repeated on days 15 and 28. Blood was removed from rabbits on day 35, allowed to coagulate overnight at 4°C. and the resulting serum stored at -20°C.

For purification of specific antibodies, resin-immobilised ligand was produced as follows: Big3 polypeptide was diluted in 0.1M sodium bicarbonate, 0.5 M NaCl, pH8.3, at 10 a concentration of 5 mg/ml in a total volume of 2 ml. This was reacted for two hours at room temperature with 2 ml of cyanogen bromide-activated Sepaharose CL-4B resin (Sigma Chemical Co. St Louis, MO). After reaction, the resin was washed three times in 15 10 volumes of 100 mM Tris, 500 mM NaCl, pH 7.5. Immune serum was incubated with the affinity resin for two hours at 4°C, after which resin was washed in a 5 ml glass chromatography column (Bio-Rad, Richmond CA) for with 25 volumes of 100 mM Tris, 500 mM NaCl, pH 7.5. Specific antibodies were eluted in 1 ml aliquots with 100 mM Glycine/HCl, pH 2.8. Elution of antibody was followed by monitoring the optical density at 20 280 nM (OD280), and fractions with an OD280 of greater than 1 were pooled and dialysed (Slide-A-lyzer cassettes, Pierce) for 36 hours at 4°C against 1 liter PBS, with three changes of buffer.

Binding and signalling of angiostatin via the ABP-1 protein

Figures 9A and 9B show data of binding of FITC-labeled angiostatin to ABP-1 transfected HeLa and EaHy926 cells transfected with the vector control. In particular figure 25 9A shows the cellular localization of ABP-1 fused to green fluorescent protein (GFP) in transiently transfected cells. The protein can be detected in the endoplasmic reticulum and the cell membrane. DABP-1 contains a 500bp deletion in the 5'end of the gene, which disrupts the previously described localization of ABP-1.

Figure 9B shows HeLa cells transfected with ABP-1 GFP. Incubation with 2.5 mg of 30 angiostatin for 60 minutes at 0°C and subsequent incubation for 15 minutes at 37°C induces internalization of ABP-1-GFP.

Figure 9C shows the binding of angiostatin to ABP-1. We have shown that fluorescein isothiocyanate (FITC)-labelled angiostatin binds specifically to endothelial cells (data not shown). We have transfected HeLa cells with either the ABP-1 expression construct or the vector control (p RC/CMV, In Vitrogen, Inc.). We incubated live HeLa 5 cells FITC-labelled angiostatin (10ug/ml) in DMEM+10% fetal calf serum at 0°C for 60 minutes. The cells were then incubated at 37°C at 15 minutes to aggregate bound angiostatin. Binding was analyzed with a fluorescent microscope. Binding of angiostatin was detected in ABP-1 transfected cells but not in the vector control.

Figure 9D shows immunostaining of ABP-1 in Human umbilical cord endothelial 10 (HUVE) cells together with staining against F-actin with rhodamin-labelled phalloidin.

•*Immunostaining protocol:*

HUVE cells were fixed in 4 % formaldehyde, washed in PBS and preblocked in 5% horse serum. The blocking solution was removed and replaced by rabbit polyclonal antibodies against the angiostatin-binding domain Big3 diluted in 5% horse serum. Positive 15 staining was visualized with a fluorescence-labeled secondary antibody (Dako, Inc.). Rhodamin-conjugated phalloidin (Molecular Probes, Inc.) was stained simultaneously with the secondary antibody (after permeabilization with 1%triton X100 for 1 minute). Rabbit polyclonal antibodies against green fluorescent protein was used as a negative control. In addition no positive staining could be detected in human fibroblasts.

As can be seen in Fig. 9D, ABP-1 is localized in focal adhesions and membrane ruffles (arrows).

In vitro kinase data

Huve cells were plated subconfluent in 5cm Petri dishes. Angiostatin was added at 2.5 25 mg/ml at different time points the following day. All plates including controls were harvested simultanously. The cells were rinsed in ice cold PBS and incubated in 1ml lysis buffer. The cells were transferred to an eppendorf tube and centrifuged at 14 000rpm for 5 minutes at 4°C. The supernatant was transferred to another eppendorf tube and 2µg of Big 3 rabbit polyclonal antibodies was added. The samples were incubated for 60 min. at 4°C and 30 subsequently 50µl of a protein A sepharose (Pharmacia, Inc.) slurry was added and incubated for another 60 min. in a rotating incubator. The immunoprecipitates were collected by brief centrifugation and washed two times in lysis buffer, once in washing

buffer and once in kinase buffer. Residual buffer was removed with a syringe. 25 µl of kinase buffer was added to each tube together with 1µCi gammaATP (Amersham, Inc.). The samples were incubated at R.T. for 20 minutes. The reaction was stopped by adding 2xSDS PAGE sample buffer. The samples were boiled under denaturing conditions and 5 subsequently analyzed by SDS PAGE.

The data illustrated in Figure 10 show that addition of angiostatin downregulates ABP-1 associated kinase activity within 30 minutes. This is direct proof that angiostatin affects signalling pathways that are mediated by ABP-1.

10 *ABP-1 mediates Angiostatin-induced focal adhesion kinase activity.*

The data illustrated by Figure 11 show that addition of 2.5 µg/ml of angiostatin upregulates FAK activity within 1 hour after addition.

EaHy926 cells were plated subconfluent in 5cm Petri dishes. Angiostatin was added at 2.5 µg/ml at different time points the following day. All plates including controls were 15 harvested simultaneously. The cells were rinsed in ice cold PBS and incubated in 1ml lysis buffer. The cells were transferred to an eppendorf tube and centrifuged at 14 000rpm for 5 minutes at 4°C. The supernatant was transferred to another eppendorf tube and 1ug of FAK monoclonal antibody (Transduction Lab. Inc.) was added. The samples were incubated for 60 min. at 4°C and subsequently rabbit anti-mouse IgG + 50µl of a protein A sepharose 20 (Pharmacia, Inc.) slurry was added and incubated for another 60 min. in a rotating incubator. The immunoprecipitates were collected by brief centrifugation and washed two times in lysis buffer, once in washing buffer and once in kinase buffer. Residual buffer was removed with a syringe. 25 µl of kinase buffer was added to each tube together with 1µCi γATP (Amersham, Inc.). The samples were incubated at R.T. for 20 minutes. The reaction 25 was stopped by adding 2xSDS PAGE sample buffer. The samples were boiled under denaturing conditions and subsequently analyzed by SDS PAGE.

As can be seen in Fig. 11, addition of angiostatin upregulates FAK activity within 1 hour. It should be noted that EaHy926 cells are not expressing ABP1 as demonstrated by reverse transcriptase PCR analysis.

CLAIMS

1. An isolated human angiogenesis-associated protein capable of binding an N-terminal fragment of plasminogen.
- 5 2. The protein of claim 1 wherein the N-terminal fragment of plasminogen is constituted by the kringle domains 1 to 4 of plasminogen.
3. The protein of claim 1 or 2 comprising an amino acid sequence having at least approximately 80% sequence homology, preferably approximately 90% sequence homology, more preferably approximately 95% sequence homology and most preferably approximately 98% sequence homology to SEQ ID NOs.2, 3 or 4.
- 10 4. The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 2.
5. The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 3, wherein the amino acid residue in position 135 is Asn, Ser or Asp and the three amino acid residues in positions 148 to 150 are the tripeptide Glu-Leu-Ala or the tripeptide Thr-Trp-Pro.
- 15 6. The protein of claim 3 which comprises the amino acid sequence of SEQ ID NO. 4.
7. A peptide capable of binding an N-terminal fragment of plasminogen and which has an amino acid sequence comprising at least 5 contiguous amino acid residues of SEQ ID NO. 2.
- 20 8. A peptide according to claim 7 which has an amino acid sequence comprising at least 10 contiguous amino acid residues of SEQ ID NO. 2.
9. An isolated nucleic acid molecule comprising a sequence that codes for a protein or peptide according to any one of claims 3 to 8.
- 25 10. The isolated nucleic acid molecule of claim 9 encoding the protein of claim 4.
11. The isolated nucleic acid molecule of claim 9 encoding the protein of claim 5.
12. The isolated nucleic acid molecule of claim 9 encoding the protein of claim 6.
- 30 13. The isolated nucleic acid molecule of any one of claims 10 to 12 comprising at least the sequence from nucleotide 2177 to nucleotide 2608 of SEQ ID NO. 1.
14. The isolated nucleic acid molecule of claim 9 comprising the sequence from nucleotide 797 to nucleotide 2824 of SEQ ID NO. 1.

15. The isolated nucleic acid molecule of claim 14 consisting of the sequence of SEQ ID NO.1.
16. A nucleic acid molecule encoding a peptide according to claim 7 or 8.
- 5 17. A nucleic acid capable of specifically hybridizing, under stringent conditions, to a nucleic acid according to claim 9 to 16.
18. A vector comprising a nucleic acid according to any one of claims 9 to 17.
19. The vector of claim 18 which is a plasmid.
20. The vector of claim 18 which is a virus.
- 10 21. A recombinant cell transformed or transfected with the vector of claim 18.
22. An antibody or antibody fragment which specifically binds a protein or peptide according to any one of claims 3 to 8.
23. An antibody according to claim 22 which is a monoclonal antibody or fragment thereof.
- 15 24. The antibody of claims 22 or 23 for use as a medicament.
25. A recombinant cell expressing the antibody according to claims 22 or 23.
26. A screening method for identifying a compound capable of interacting with a protein according to any one of claims 1 to 6.
27. A compound identified through the screening method of claim 26.
- 20 28. The proteins, peptides or compounds of any one of claims 1 to 8 and 27 for use as a medicament.
29. Use of the proteins, peptides or compounds according to any one of claims 1 to 8 and 27 in the manufacture of a medicament directed towards an angiogenesis-related disease or disorder.
- 25 30. A pharmaceutical preparation comprising a protein, peptide or compound according to any one of claims 1 to 8 and 27 together with a pharmaceutically acceptable carrier.




Fig. 1




Fig. 2

-His, +3-AT




Fig. 3

Angiostatin **Plasminogen**

Big-3 RO **Big-3 RO**

Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8



Fig. 9A




Fig. 9B




Fig. 9C




Fig. 9D





Fig. 10



SEQUENCE LISTING

<110> Pharmacia & Upjohn

<120> Angiogenesis related molecules

<130> pctphal856

<140>

<141>

<150> SE9804372-2

<151> 1998-12-17

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 6463

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (797)..(2824)

<400> 1

ccaggagctg ccttggcagt cacgcccctt ccttcggagg agctttctgg ctgcctaaac 60

tggtagaccc cctgaattac tctccatct ccgtctcttt tcgcctcttc ttctcttagt 120

tctctcgcc tccccctcaa ctaccaccac ctccagtcag tctcgctcc ggctatccgc 180

tgctccaccc tctggcccg ttcctgcgt gtccgctgcc accaaggaga gcccggacgg 240

agcagcgagg aggggagcag ccgggagttg gggcttcccc cctgcccata cctggccgct 300

ggcccgccgac cgaagccact tgagcgagca gagagtcgtc accttgtctt cttgccttc 360

agggagctgc taagaaggac aaataagata gcagagtcaa agagctttg ttccttaga 420

aggaaggctg agaaaactaaa ggccagcgca ggacatctca ttgccattgt cagccaggaa 480

ctcgagcct cacagcccta cttttctct gacctctggg gggtccttgc cttgtctaca 540

atctccacca tccactagat tgtctcctgc ccgacacccc ttggtcccaa accagggaga 600

ccattcagct cacctgccta ggccgcagca gcatttcctt cctaattcagg ctcaccagg 660

ggatcattac cgtctctccc aacctggcct gagtcagcag cagcagcaac agcagcagca 720

gcaccatcat caccatcacc accaacaaca gcagcagcag cagccacagc agcagccagg 780
 agaaggctat tcagct atg cct cgg gct cag cca tcc tct gct tct tat cag 832
 Met Pro Arg Ala Gln Pro Ser Ser Ala Ser Tyr Gln
 1 5 10

 cca gtg cca gca gac cct ttt gcc att gtt tcc aga gcc cag cag atg 880
 Pro Val Pro Ala Asp Pro Phe Ala Ile Val Ser Arg Ala Gln Gln Met
 15 20 25

 gtt gag atc ctc tca gac gag aac cgg aac ttg agg caa gag ttg gaa 928
 Val Glu Ile Leu Ser Asp Glu Asn Arg Asn Leu Arg Gln Glu Leu Glu
 30 35 40

 gga tgc tat gag aag gtg gca aga ctg cag aag gtg gag aca gaa atc 976
 Gly Cys Tyr Glu Lys Val Ala Arg Leu Gln Lys Val Glu Thr Glu Ile
 45 50 55 60

 cag cgc gtc tcg gag gca tat gag aac ctc gtg aag tca tcc tcc aaa 1024
 Gln Arg Val Ser Glu Ala Tyr Glu Asn Leu Val Lys Ser Ser Ser Lys
 65 70 75

 aga gag gcc cta gag aaa gcc atg aga aac aag cta gag ggc gag att 1072
 Arg Glu Ala Leu Glu Lys Ala Met Arg Asn Lys Leu Glu Gly Glu Ile
 80 85 90

 cg agg atg cat gat ttc aac agg gat ctg aga gag cgt cta gag act 1120
 Arg Arg Met His Asp Phe Asn Arg Asp Leu Arg Glu Arg Leu Glu Thr
 95 100 105

 gcc aac aag cag ctt gca gag aag gaa tat gag ggg tca gag gac acc 1168
 Ala Asn Lys Gln Leu Ala Glu Lys Glu Tyr Glu Ser Glu Asp Thr
 110 115 120

 aga aaa acc atc tcg cag ctc ttt gca aaa aat aaa gaa agc cag cgt 1216
 Arg Lys Thr Ile Ser Gln Leu Phe Ala Lys Asn Lys Glu Ser Gln Arg
 125 130 135 140

 gag aag gag aag ctg gaa gcg gag ctg gcc act gcc cgt tct acc aat 1264
 Glu Lys Glu Lys Leu Glu Ala Glu Leu Ala Thr Ala Arg Ser Thr Asn
 145 150 155

 gag gac caa aga cga cac atc gaa atc cga gat cag gcc ctg agt aat 1312
 Glu Asp Gln Arg Arg His Ile Glu Ile Arg Asp Gln Ala Leu Ser Asn
 160 165 170

 gcc cag gcc aag gtg gta aag ctg gaa gaa gag ctg aaa aag aag caa 1360
 Ala Gln Ala Lys Val Val Lys Leu Glu Glu Leu Lys Lys Lys Gln
 175 180 185

gtg tac gtt gac aag gtg gag aag atg cag cag gcc ctt gta cag ctc	1408
Val Tyr Val Asp Lys Val Glu Lys Met Gln Gln Ala Leu Val Gln Leu	
190 195 200	
cag gca gca tgt gaa aaa cgt gag cag cta gag cac cgt ctc cgg aca	1456
Gln Ala Ala Cys Glu Lys Arg Glu Gln Leu Glu His Arg Leu Arg Thr	
205 210 215 220	
cga ctg gag agg gaa ctg gaa tcc ctg aga atc cag cag cgt cag ggc	1504
Arg Leu Glu Arg Glu Leu Glu Ser Leu Arg Ile Gln Gln Arg Gln Gly	
225 230 235	
aac tgt cag ccc acc aac gtt tca gaa tac aat gct gcc gca ctg atg	1552
Asn Cys Gln Pro Thr Asn Val Ser Glu Tyr Asn Ala Ala Leu Met	
240 245 250	
gag ctc ctt cgg gag aaa gag gag att ctg gct ctg gaa gct gat	1600
Glu Leu Leu Arg Glu Lys Glu Glu Arg Ile Leu Ala Leu Glu Ala Asp	
255 260 265	
atg aca aag tgg gag cag aaa tat ttg gag gag aat gtg atg aga cat	1648
Met Thr Lys Trp Glu Gln Lys Tyr Leu Glu Glu Asn Val Met Arg His	
270 275 280	
ttt gct ctg gat gct gct gca act gtg gct gct cag agg gac aca aca	1696
Phe Ala Leu Asp Ala Ala Thr Val Ala Ala Gln Arg Asp Thr Thr	
285 290 295 300	
gtc atc agt cac tct cct aac acc agc tat gac aca gct cta gaa gct	1744
Val Ile Ser His Ser Pro Asn Thr Ser Tyr Asp Thr Ala Leu Glu Ala	
305 310 315	
cgc atc cag aaa gag gag gaa gaa atc ttg atg gcc aat aag cgt tgc	1792
Arg Ile Gln Lys Glu Glu Glu Ile Leu Met Ala Asn Lys Arg Cys	
320 325 330	
ctt gac atg gag ggc agg att aag acc ctc cat gcc cag att att gag	1840
Leu Asp Met Glu Gly Arg Ile Lys Thr Leu His Ala Gln Ile Ile Glu	
335 340 345	
aag gat gcc atg atc aaa gta ctc cag cag cgt tcc cgg aag gag ccg	1888
Lys Asp Ala Met Ile Lys Val Leu Gln Gln Arg Ser Arg Lys Glu Pro	
350 355 360	
agc aag aca gag cag ctg tcg tgc atg cgg cca gcg aag tct ctg atg	1936
Ser Lys Thr Glu Gln Leu Ser Cys Met Arg Pro Ala Lys Ser Leu Met	
365 370 375 380	
tcc att tcc aat gct gga tca ggc ttg ctc tcc cac tca tcc acc ctg	1984
Ser Ile Ser Asn Ala Gly Ser Gly Leu Leu Ser His Ser Ser Thr Leu	
385 390 395	

act ggc tcc ccc atc atg gaa gaa aag cga gac gac aag agc tgg aag		2032
Thr Gly Ser Pro Ile Met Glu Glu Lys Arg Asp Asp Lys Ser Trp Lys		
400	405	410
ggg agc cta ggc att ctc ctg ggt gga gac tac cgt gct gaa tat gtc		2080
Gly Ser Leu Gly Ile Leu Leu Gly Gly Asp Tyr Arg Ala Glu Tyr Val		
415	420	425
cct tcc aca ccc tcg cct gtg cca ccc tcg act ccc ctg ctc tcg gct		2128
Pro Ser Thr Pro Ser Pro Val Pro Pro Ser Thr Pro Leu Leu Ser Ala		
430	435	440
cac tcc aag aca ggc agc cga gac tgc agt acc caa act gaa cgt ggg		2176
His Ser Lys Thr Gly Ser Arg Asp Cys Ser Thr Gln Thr Glu Arg Gly		
445	450	455
460		
acg gaa tcg aac aaa act gca gct gtt gct ccc atc tct gtt cct gct		2224
Thr Glu Ser Asn Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala		
465	470	475
cca gtt gct gct gcc gcc act gct gcc gcc atc act gcc act gct gcc		2272
Pro Val Ala Ala Ala Ala Thr Ala Ala Ile Thr Ala Thr Ala Ala		
480	485	490
acc atc acc acc acc atg gta gct gct gct cca gtt gct gtt gct gct		2320
Thr Ile Thr Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala		
495	500	505
gct gct gct cca gct gct gct gcc ccg tct cca gcc act gcc gct		2368
Ala Ala Ala Pro Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala		
510	515	520
gct act gct gct gct tct cca gct gct gct ggt cag att cca gct		2416
Ala Thr Ala Ala Ala Val Ser Pro Ala Ala Gly Gln Ile Pro Ala		
525	530	535
540		
gct gcc tct gtt gcc tca gct gct gcc gtt gct cct tct gct gct gct		2464
Ala Ala Ser Val Ala Ser Ala Ala Val Ala Pro Ser Ala Ala Ala		
545	550	555
gct gct gct gtt cag gtt gct cca gct gct ccg gct cca gtt cca gct		2512
Ala Ala Ala Val Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala		
560	565	570
ccg gct ctg gtt ccg gtt cca gct cca gca gcg gct cag gct tct gct		2560
Pro Ala Leu Val Pro Val Pro Ala Pro Ala Ala Gln Ala Ser Ala		
575	580	585
cct gct cag act cag gca cca act tca gct ccg gct gtg gct cca act		2608
Pro Ala Gln Thr Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr		
590	595	600

cca gct cca act cca act cca gct gtg gct cag gct gag gtt cct gca 2656
 Pro Ala Pro Thr Pro Thr Pro Ala Val Ala Gln Ala Glu Val Pro Ala
 605 610 615 620

 agt cca gct acc ggt cct gga cca cat cgt ttg tct ata cca agt ttg 2704
 Ser Pro Ala Thr Gly Pro Gly Pro His Arg Leu Ser Ile Pro Ser Leu
 625 630 635

 acc tgc aat cca gac aaa aca gat ggg cct gtg ttc cac tcc aat act 2752
 Thr Cys Asn Pro Asp Lys Thr Asp Gly Pro Val Phe His Ser Asn Thr
 640 645 650

 ctg gaa aga aaa act ccc att cag atc ctg gga caa gag cct gat gca 2800
 Leu Glu Arg Lys Thr Pro Ile Gln Ile Leu Gly Gln Glu Pro Asp Ala
 655 660 665

 gag atg gtg gaa tat ctc atc taa acggccaaat caagagctgc agattatcg 2854
 Glu Met Val Glu Tyr Leu Ile
 670 675

 caaaaaatgct tttaatcatt ttcccccttt tattggttct tgtttgagg gtgaggacaa 2914
 gggttgtggg gagggggatgt ttttaacag gacttttat tggacaatg tactacttga 2974
 gtaataccat gtgaacacca gtctatttt gtagtgcctt ggagtacctc taaagacaga 3034
 ttaatcagaa tggctctaa agcttattgt ttgaatttat acgaatactg ggactgttaa 3094
 caggtggcta tacatcgacg tttcaatgt gcttaaattt gtttaaattt tccatattct 3154
 agatcatttt ttattgaaga gcacagttatg tggaaagac agtgtataac acgttagttt 3214
 gaagtggaa gctagagaga attgagtg tgctgtttg tatagttact atccctgtgca 3274
 gcagctggag aaagcactca cctcaggctt acaaaaaggaa atagttcag gagctatgta 3334
 agctggaaaa aaggtaggaa gtttgggt gcagaagggt actggagcta atttttctt 3394
 ccagttccc agtaccctg ccccaggaa ttgtgtttgt cttcatttca gtggtgctt 3454
 ggaaatggat tctttgggtt ccctcctgga ggttcataca ttcatatata tgctctggag 3514
 taatttatgc atttggataa ttaatatatt gcttcagat gctggagag tacattaact 3574
 gagtgatgcg caacttcctc tctcttaggg aatttagacca tcagaggcct tgatggagag 3634
 ttgcatttag taagaccaat cagcttagtg tttatttctt ctacagcaca gattcactgg 3694
 ctgggtctcc agtctcaaatt tgccaatcat ttgcaaagtg aggaaggatc tttqttqaca 3754
 ctgggtctcc agtctcaaatt tgccaatcat ttgcaaagtg aggaaggatc tttqttqaca 3814

ggttgaatgc tttgaatttc tggtgactac tttgaaataa cttgtttgt ttgtcaaatt 3874
ctaagcatat gtctaaaag gcattttga ctatcaccc caaggaaata gcttgagaaa 3934
cccaaagtac tatgctgcag tcggggaga ggtggattgc agcagtatcc tcaactacct 3994
cttctcactg tcagtgacac catctggaa tacctttggg aagcagcagg aaatgtgcat 4054
gtggtagag atcaaaggag gcaatggctc caagcctgc cataggctg cctccaagga 4114
cacagaagga tgccagttgc cacaggtccc tgccctgtgt cacctgtctg cccttcatta 4174
aggtgagaaa tctgcagata gcatcattaa gatcagttt aaggggtata gggagggta 4234
ggaaagtggg ggggtttagg taagggttgg gggtagaggt tttggatgt cttagttaga 4294
aaccagatta atagaagagt aggccctgata tattacatca tgagccatag tggggaaa 4354
gaacttttagc aatatagccc tacccctca ttttagtgat gaggaatctg agaactggag 4414
agttcagtg acttttgaa agtcatacaa cacagctaac cattatgcca atcaccatgc 4474
ttatTTTggg aaactcttta tctttttaa attccatttt atgaaaaggc atcttcatgg 4534
tccagggaat atgtatcttgc taaaatgtac ctgggtggag tagcttgtcc agtcttgaca 4594
aactactgaa ttctgtctt gcctctcctt cagtgccctt taaaaggttt tccctttct 4654
gatctgcatt tcaacataga gtcacataaa tgccccctg agaaaccaat cccacttctt 4714
tctaggagat tgggtatctt agataatctt ttgggttcc tctgtgagta taggaatgg 4774
atccttccta attatcttcc aaaggaatta tttgtgtgt gtgcctgtgt gtgtgttagag 4834
acataaagga gggtagtg atttcagct agtccttca catttcaat aatgaggtaa 4894
tcatgttaca tacacattag tcctcagtt taaagtgaat ctcagataga aattaaaagt 4954
gcagttgtgt taagactctt tcatactacc cttagtcat aaggagaaaa aaacactcaa 5014
atagtagaag cagcaagtag caaacttcag gagagctact ttctatccaa ataatttaaa 5074
aaacactttt cacctactcc tttcatggtt ataacacatt ggcagacttt ttgctggctc 5134
tgggagccat gatTTtaatc acattctgca aggtgacaaa tgtcatacat tccacattgt 5194
gtggtagcca tctctttaga ctcatgtgtt ttggggaaag gaagaagttc ttggctgagt 5254
actatTTTga actttccaga accctctcac accagagaca gttcttctt gttcagttc 5314
caatccccga taatttgcta aaataacatt gtacatccaa gagaggaaag aagagtatgt 5374

cagtatatta tgcagaagat agatacagcc tttcagaag atctccacta gttttgttc 5434
 caaaaattca agtttatggg agaaatctca attagccacc tttcacagt tgtgtggata 5494
 taacatttgg gggatcttc tggactccta cctatctgtg cattttaccc gcacctcagg 5554
 aaaggagggt gaccagggtt tcttagctt tactgcttg tgatctctga ggaccttcta 5614
 attcagttgt accccagtgt tccatgtata gaaaaacttc attagaacaa actttacttg 5674
 atatgaaact cctattaaca gtctttttt gaaataaaaaa gtagcttgag ctttctttta 5734
 aatatcatgta tcttgattgt tgatttaatg aaggatttcc tttaatgtc gctttgagc 5794
 ttcaaggtaa taggacagca ggaacctaaa atatctgcca tcatacgcca taggaaagat 5854
 acccagagac ccatcatgtt ctcttttgt tgttacactg ttgggtgggt ataacaattg 5914
 gaaaaatgaac aaactgattt attgtgcaaa ctactttta tgacaaggct aaaccctcat 5974
 aatgcggcag cttaaagtgt atacatatgc actaactttt atcaattata ttctcatatc 6034
 tgtagctac acagtctcct attatctcaa ttgcttatgt gcatatggaa tatgttactt 6094
 aaaacgtgtg cattctact gaaaatgttt tcaaaggaag gtatcagctg tgggctaatt 6154
 gccaccaatt tcagcctgcc acgatttttg gaaatatgtc ttccaagtgc catccatcat 6214
 cagtaggaca agtgcggga gtttgttat tttttccag tagcaacgat gggttacatg 6274
 gagccatgaa acctccttct ggcctccctt gtgattaatg gcatgtgttt gtaaaatgga 6334
 tagctgggt tggcagatgg ctagagaaga atcgccttg gttaaaatg tatgtggtcc 6394
 cctaatttattt gtgacccat tctgtaatca actgagctag ttccaataaa gttaagcagg 6454
 tttaaatcc 6463

<210> 2
 <211> 675
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Pro Arg Ala Gln Pro Ser Ser Ala Ser Tyr Gln Pro Val Pro Ala
 1 5 10 15

Asp Pro Phe Ala Ile Val Ser Arg Ala Gln Gln Met Val Glu Ile Leu
 20 25 30

Ser Asp Glu Asn Arg Asn Leu Arg Gln Glu Leu Glu Gly Cys Tyr Glu
 35 40 45

Lys Val Ala Arg Leu Gln Lys Val Glu Thr Glu Ile Gln Arg Val Ser
 50 55 60

Glu Ala Tyr Glu Asn Leu Val Lys Ser Ser Ser Lys Arg Glu Ala Leu
 65 70 75 80

Glu Lys Ala Met Arg Asn Lys Leu Glu Gly Glu Ile Arg Arg Met His
 85 90 95

Asp Phe Asn Arg Asp Leu Arg Glu Arg Leu Glu Thr Ala Asn Lys Gln
 100 105 110

Leu Ala Glu Lys Glu Tyr Glu Gly Ser Glu Asp Thr Arg Lys Thr Ile
 115 120 125

Ser Gln Leu Phe Ala Lys Asn Lys Glu Ser Gln Arg Glu Lys Glu Lys
 130 135 140

Leu Glu Ala Glu Leu Ala Thr Ala Arg Ser Thr Asn Glu Asp Gln Arg
 145 150 155 160

Arg His Ile Glu Ile Arg Asp Gln Ala Leu Ser Asn Ala Gln Ala Lys
 165 170 175

Val Val Lys Leu Glu Glu Leu Lys Lys Gln Val Tyr Val Asp
 180 185 190

Lys Val Glu Lys Met Gln Gln Ala Leu Val Gln Leu Gln Ala Ala Cys
 195 200 205

Glu Lys Arg Glu Gln Leu Glu His Arg Leu Arg Thr Arg Leu Glu Arg
 210 215 220

Glu Leu Glu Ser Leu Arg Ile Gln Gln Arg Gln Gly Asn Cys Gln Pro
 225 230 235 240

Thr Asn Val Ser Glu Tyr Asn Ala Ala Leu Met Glu Leu Leu Arg
 245 250 255

Glu Lys Glu Glu Arg Ile Leu Ala Leu Glu Ala Asp Met Thr Lys Trp
 260 265 270

Glu Gln Lys Tyr Leu Glu Glu Asn Val Met Arg His Phe Ala Leu Asp
 275 280 285

Ala Ala Ala Thr Val Ala Ala Gln Arg Asp Thr Thr Val Ile Ser His
 290 295 300

Ser Pro Asn Thr Ser Tyr Asp Thr Ala Leu Glu Ala Arg Ile Gln Lys
305 310 315 320

Glu Glu Glu Glu Ile Leu Met Ala Asn Lys Arg Cys Leu Asp Met Glu
325 330 335

Gly Arg Ile Lys Thr Leu His Ala Gln Ile Ile Glu Lys Asp Ala Met
340 345 350

Ile Lys Val Leu Gln Gln Arg Ser Arg Lys Glu Pro Ser Lys Thr Glu
355 360 365

Gln Leu Ser Cys Met Arg Pro Ala Lys Ser Leu Met Ser Ile Ser Asn
370 375 380

Ala Gly Ser Gly Leu Leu Ser His Ser Ser Thr Leu Thr Gly Ser Pro
385 390 395 400

Ile Met Glu Glu Lys Arg Asp Asp Lys Ser Trp Lys Gly Ser Leu Gly
405 410 415

Ile Leu Leu Gly Gly Asp Tyr Arg Ala Glu Tyr Val Pro Ser Thr Pro
420 425 430

Ser Pro Val Pro Pro Ser Thr Pro Leu Leu Ser Ala His Ser Lys Thr
435 440 445

Gly Ser Arg Asp Cys Ser Thr Gln Thr Glu Arg Gly Thr Glu Ser Asn
450 455 460

Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala Pro Val Ala Ala
465 470 475 480

Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala Thr Ile Thr Thr
485 490 495

Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala Ala Ala Pro
500 505 510

Ala Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala Ala Thr Ala Ala
515 520 525

Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala Ala Ala Ser Val
530 535 540

Ala Ser Ala Ala Ala Val Ala Pro Ser Ala Ala Ala Ala Ala Val
545 550 555 560

Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala Pro Ala Leu Val
565 570 575

Pro Val Pro Ala Pro Ala Ala Ala Gln Ala Ser Ala Pro Ala Gln Thr
580 585 590

Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr Pro Ala Pro Thr
595 600 605

Pro Thr Pro Ala Val Ala Gln Ala Glu Val Pro Ala Ser Pro Ala Thr
610 615 620

Gly Pro Gly Pro His Arg Leu Ser Ile Pro Ser Leu Thr Cys Asn Pro
625 630 635 640

Asp Lys Thr Asp Gly Pro Val Phe His Ser Asn Thr Leu Glu Arg Lys
645 650 655

Thr Pro Ile Gln Ile Leu Gly Gln Glu Pro Asp Ala Glu Met Val Glu
660 665 670

Tyr Leu Ile
675

<210> 3
<211> 675
<212> PRT
<213> Homo sapiens

<220>
<221> VARIANT
<222> (...)
<223> Residue 135 = Asn, Ser or Asp

<220>
<221> VARIANT
<222> (...) (150)
<223> Residues 148-150 = Glu-Leu-Ala or Thr-Thr-Pro

<400> 3
Met Pro Arg Ala Gln Pro Ser Ser Ala Ser Tyr Gln Pro Val Pro Ala
1 5 10 15

Asp Pro Phe Ala Ile Val Ser Arg Ala Gln Gln Met Val Glu Ile Leu
20 25 30

Ser Asp Glu Asn Arg Asn Leu Arg Gln Glu Leu Glu Gly Cys Tyr Glu
35 40 45

Lys Val Ala Arg Leu Gln Lys Val Glu Thr Glu Ile Gln Arg Val Ser
50 55 60

Glu Ala Tyr Glu Asn Leu Val Lys Ser Ser Ser Lys Arg Glu Ala Leu
65 70 75 80

Glu Lys Ala Met Arg Asn Lys Leu Glu Gly Glu Ile Arg Arg Met His
85 90 95

Asp Phe Asn Arg Asp Leu Arg Glu Arg Leu Glu Thr Ala Asn Lys Gln
100 105 110

Leu Ala Glu Lys Glu Tyr Glu Gly Ser Glu Asp Thr Arg Lys Thr Ile
115 120 125

Ser Gln Leu Phe Ala Lys Xaa Lys Glu Ser Gln Arg Glu Lys Glu Lys
130 135 140

Leu Glu Ala Xaa Xaa Xaa Thr Ala Arg Ser Thr Asn Glu Asp Gln Arg
145 150 155 160

Arg His Ile Glu Ile Arg Asp Gln Ala Leu Ser Asn Ala Gln Ala Lys
165 170 175

Val Val Lys Leu Glu Glu Leu Lys Lys Gln Val Tyr Val Asp
180 185 190

Lys Val Glu Lys Met Gln Gln Ala Leu Val Gln Leu Gln Ala Ala Cys
195 200 205

Glu Lys Arg Glu Gln Leu Glu His Arg Leu Arg Thr Arg Leu Glu Arg
210 215 220

Glu Leu Glu Ser Leu Arg Ile Gln Gln Arg Gln Gly Asn Cys Gln Pro
225 230 235 240

Thr Asn Val Ser Glu Tyr Asn Ala Ala Ala Leu Met Glu Leu Leu Arg
245 250 255

Glu Lys Glu Glu Arg Ile Leu Ala Leu Glu Ala Asp Met Thr Lys Trp
260 265 270

Glu Gln Lys Tyr Leu Glu Glu Asn Val Met Arg His Phe Ala Leu Asp
275 280 285

Ala Ala Ala Thr Val Ala Ala Gln Arg Asp Thr Thr Val Ile Ser His
290 295 300

Ser Pro Asn Thr Ser Tyr Asp Thr Ala Leu Glu Ala Arg Ile Gln Lys
305 310 315 320

Glu Glu Glu Ile Leu Met Ala Asn Lys Arg Cys Leu Asp Met Glu
325 330 335

Gly Arg Ile Lys Thr Leu His Ala Gln Ile Ile Glu Lys Asp Ala Met
340 345 350

Ile Lys Val Leu Gln Gln Arg Ser Arg Lys Glu Pro Ser Lys Thr Glu
355 360 365

Gln Leu Ser Cys Met Arg Pro Ala Lys Ser Leu Met Ser Ile Ser Asn
370 375 380

Ala Gly Ser Gly Leu Leu Ser His Ser Ser Thr Leu Thr Gly Ser Pro
385 390 395 400

Ile Met Glu Glu Lys Arg Asp Asp Lys Ser Trp Lys Gly Ser Leu Gly
405 410 415

Ile Leu Leu Gly Gly Asp Tyr Arg Ala Glu Tyr Val Pro Ser Thr Pro
420 425 430

Ser Pro Val Pro Pro Ser Thr Pro Leu Leu Ser Ala His Ser Lys Thr
435 440 445

Gly Ser Arg Asp Cys Ser Thr Gln Thr Glu Arg Gly Thr Glu Ser Asn
450 455 460

Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala Pro Val Ala Ala
465 470 475 480

Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala Thr Ile Thr Thr
485 490 495

Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala Ala Ala Pro
500 505 510

Ala Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala Ala Thr Ala Ala
515 520 525

Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala Ala Ala Ser Val
530 535 540

Ala Ser Ala Ala Ala Val Ala Pro Ser Ala Ala Ala Ala Ala Val
545 550 555 560

Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala Pro Ala Leu Val
565 570 575

Pro Val Pro Ala Pro Ala Ala Gln Ala Ser Ala Pro Ala Gln Thr
580 585 590

Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr Pro Ala Pro Thr
595 600 605

Pro Thr Pro Ala Val Ala Gln Ala Glu Val Pro Ala Ser Pro Ala Thr
610 615 620

Gly Pro Gly Pro His Arg Leu Ser Ile Pro Ser Leu Thr Cys Asn Pro
625 630 635 640

Asp Lys Thr Asp Gly Pro Val Phe His Ser Asn Thr Leu Glu Arg Lys
645 650 655

Thr Pro Ile Gln Ile Leu Gly Gln Glu Pro Asp Ala Glu Met Val Glu
660 665 670

Tyr Leu Ile
675

<210> 4

<211> 143

<212> PRT

<213> Homo sapiens

<400> 4

Glu Ser Asn Lys Thr Ala Ala Val Ala Pro Ile Ser Val Pro Ala Pro
1 5 10 15

Val Ala Ala Ala Ala Thr Ala Ala Ala Ile Thr Ala Thr Ala Ala Thr
20 25 30

Ile Thr Thr Thr Met Val Ala Ala Ala Pro Val Ala Val Ala Ala Ala
35 40 45

Ala Ala Pro Ala Ala Ala Ala Pro Ser Pro Ala Thr Ala Ala Ala
50 55 60

Thr Ala Ala Ala Val Ser Pro Ala Ala Ala Gly Gln Ile Pro Ala Ala
65 70 75 80

Ala Ser Val Ala Ser Ala Ala Val Ala Pro Ser Ala Ala Ala
85 90 95

Ala Ala Val Gln Val Ala Pro Ala Ala Pro Ala Pro Val Pro Ala Pro
100 105 110

Ala Leu Val Pro Val Pro Ala Pro Ala Ala Gln Ala Ser Ala Pro
115 120 125

Ala Gln Thr Gln Ala Pro Thr Ser Ala Pro Ala Val Ala Pro Thr
130 135 140

<210> 5

<211> 31

<212> DNA

<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for PCR reaction

<400> 5
tacggatccg aatcgaacaa aactgcagct g

31

<210> 6
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for PCR reaction

<400> 6
atactcgagt catggagctg gagttggagc ca

32

<210> 7
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for PCR reaction

<400> 7
gtttgacctg caatccagac aa

22

<210> 8
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for PCR reaction

<400> 8
cccaggatct gaatgggagt t

21

<210> 9
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for PCR reaction

<400> 9
cagatggcc tgtgttccac tccaa

25

<210> 10
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for RACE PCR reaction

<400> 10
gctgacagt gcccgtacgc tgct

24

<210> 11
<211> 24
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for RACE PCR reaction

<400> 11
cggagacggt gctctagctg ctca

24

<210> 12
<211> 27
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:oligonucleotide
primer for RACE PCR reaction

<400> 12
tccttccaac tcttgccctca agttccg

27

<210> 13
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide
primer for RACE PCR reaction

<400> 13

ggtggcagcg gacaggcagg atac

24

<210> 14

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide
primer for RACE PCR reaction

<400> 14

gaggcggaga gaactaagag aaga

24

<210> 15

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:oligonucleotide
primer for RACE PCR reaction

<400> 15

gagcggagat ggaggagtaa ttca

24

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/04109

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/12 C12N5/10 C12N1/21 C07K14/71 C07K16/28
 G01N33/50 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 206 400 A (TNO) 30 December 1986 (1986-12-30) claims 2,8 ---	1,2, 26-30
X	KOST C ET AL: "Limited plasmin proteolysis of vitronectin. Characterization of the adhesion protein as morpho-regulatory and angiostatin-binding factor" EUR J BIOCHEM, vol. 236, no. 2, 1 March 1996 (1996-03-01), pages 682-688, XP002121364 figure 3 --- -/-	1,2

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
3 November 1999	17/11/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Authorized officer Lonnoy, O

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/04109

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMSTS E.M.B.L. Databases Accession Number: G16015, 25 January 1996 (1996-01-25) MURRAY M ET AL: "Human STS CHLC.GCT14C05.P16699" XP002121366 92.9% identity in 280bp overlap with SeqIdNo.1 abstract</p> <p>---</p>	17
A	<p>CLAESSON-WELSH L ET AL: "Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 95, no. 10, 12 May 1998 (1998-05-12), pages 5579-5583, XP002121365 abstract</p> <p>---</p>	1-30
P,A	<p>MOSER T ET AL: "Angiostatin binds ATP synthase on the surface of human endothelial cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 96, no. 6, 16 March 1999 (1999-03-16), pages 2811-2816, XP002121371</p> <p>-----</p>	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/04109

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
See FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/EP 99 04109

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

A compound or group of compounds is not sufficiently defined only by its pharmacological parameters or properties: for a fully valid definition of a compound or a group of compounds, a structural definition is needed. A complete search of the subject-matter of claims 27-30 is virtually impossible because it is not exhaustively known which chemical compounds are comprised by the scope of these claims.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/04109

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0206400	A	30-12-1986	NL 8501682 A	02-01-1987
			AT 48142 T	15-12-1989
			JP 1956575 C	10-08-1995
			JP 6076438 B	28-09-1994
			JP 62181299 A	08-08-1987
			US 5064942 A	12-11-1991
			US 4853220 A	01-08-1989